Literature DB >> 31167558

Type 2 Diabetes Mellitus and Heart Failure: A Scientific Statement From the American Heart Association and the Heart Failure Society of America: This statement does not represent an update of the 2017 ACC/AHA/HFSA heart failure guideline update.

Shannon M Dunlay, Michael M Givertz, David Aguilar, Larry A Allen, Michael Chan, Akshay S Desai, Anita Deswal, Victoria Vaughan Dickson, Mikhail N Kosiborod, Carolyn L Lekavich, Rozalina G McCoy, Robert J Mentz, Ileana L Piña.   

Abstract

Type 2 diabetes mellitus is a risk factor for incident heart failure and increases the risk of morbidity and mortality in patients with established disease. Secular trends in the prevalence of diabetes mellitus and heart failure forecast a growing burden of disease and underscore the need for effective therapeutic strategies. Recent clinical trials have demonstrated the shared pathophysiology between diabetes mellitus and heart failure, the synergistic effect of managing both conditions, and the potential for diabetes mellitus therapies to modulate the risk of heart failure outcomes. This scientific statement on diabetes mellitus and heart failure summarizes the epidemiology, pathophysiology, and impact of diabetes mellitus and its control on outcomes in heart failure; reviews the approach to pharmacological therapy and lifestyle modification in patients with diabetes mellitus and heart failure; highlights the value of multidisciplinary interventions to improve clinical outcomes in this population; and outlines priorities for future research.

Entities:  

Keywords:  AHA Scientific Statement; diabetes mellitus, type 2; drug therapy; heart failure; lifestyle; risk factors

Mesh:

Year:  2019        PMID: 31167558     DOI: 10.1161/CIR.0000000000000691

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  86 in total

Review 1.  Heart failure in patients with type 2 diabetes mellitus: assessment with echocardiography and effects of antihyperglycemic treatments.

Authors:  Katsuomi Iwakura
Journal:  J Echocardiogr       Date:  2019-10-15

2.  Effectiveness of sodium-glucose co-transporter-2 inhibitors on ischaemic heart disease.

Authors:  Yun Shen; Jian Zhou; Lizheng Shi; Elizabeth Nauman; Peter T Katzmarzyk; Eboni G Price-Haywood; Ronald Horswell; San Chu; Shengping Yang; Alessandra N Bazzano; Somesh Nigam; Gang Hu
Journal:  Diabetes Obes Metab       Date:  2020-03-31       Impact factor: 6.577

Review 3.  Update on the Impact of Comorbidities on the Efficacy and Safety of Heart Failure Medications.

Authors:  Christine Chow; Robert J Mentz; Stephen J Greene
Journal:  Curr Heart Fail Rep       Date:  2021-04-09

4.  When belongingness backfires: experienced discrimination predicts increased cardiometabolic risk among college students high in social belonging.

Authors:  Maryam Hussain; Angela E Johnson; Jacqueline Hua; Bianca M Hinojosa; Matthew J Zawadzki; Jennifer L Howell
Journal:  J Behav Med       Date:  2021-04-27

5.  Effects of Liraglutide on Worsening Renal Function Among Patients With Heart Failure With Reduced Ejection Fraction: Insights From the FIGHT Trial.

Authors:  Brahim Redouane; Stephen J Greene; Marat Fudim; Muthiah Vaduganathan; Andrew P Ambrosy; Jie-Lena Sun; Adam D DeVore; Steven E McNulty; Robert J Mentz; Adrian F Hernandez; G Michael Felker; Lauren B Cooper; Barry A Borlaug; Eric J Velazquez; Kenneth B Margulies; Abhinav Sharma
Journal:  Circ Heart Fail       Date:  2020-05-04       Impact factor: 8.790

Review 6.  Bridging the Gap for Patients with Diabetes and Cardiovascular Disease Through Cardiometabolic Collaboration.

Authors:  Lee-Shing Chang; Muthiah Vaduganathan; Jorge Plutzky; Vanita R Aroda
Journal:  Curr Diab Rep       Date:  2019-12-04       Impact factor: 4.810

7.  Adoption of New Glucose-Lowering Medications in the U.S.-The Case of SGLT2 Inhibitors: Nationwide Cohort Study.

Authors:  Rozalina G McCoy; Hayley J Dykhoff; Lindsey Sangaralingham; Joseph S Ross; Pinar Karaca-Mandic; Victor M Montori; Nilay D Shah
Journal:  Diabetes Technol Ther       Date:  2019-10-09       Impact factor: 6.118

Review 8.  Heart failure and diabetes: role of ATM.

Authors:  Mary C Wingard; Chad R Frasier; Mahipal Singh; Krishna Singh
Journal:  Curr Opin Pharmacol       Date:  2020-08-01       Impact factor: 5.547

Review 9.  Promising roles of sodium-glucose cotransporter 2 inhibitors in heart failure prevention and treatment.

Authors:  Atsushi Tanaka; Koichi Node
Journal:  Diabetol Int       Date:  2020-06-11

10.  Sacubitril-valsartan improves conduit vessel function and functional capacity and reduces inflammation in heart failure with reduced ejection fraction.

Authors:  Kanokwan Bunsawat; Stephen M Ratchford; Jeremy K Alpenglow; Soung Hun Park; Catherine L Jarrett; Josef Stehlik; Adam S Smith; Russell S Richardson; D Walter Wray
Journal:  J Appl Physiol (1985)       Date:  2020-11-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.